Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 309 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable... July 1, 2021 Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in... March 3, 2021 Cancer Won’t Wait: “I prayed she would see her daughter start... October 11, 2021 Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with... August 2, 2022 Load more HOT NEWS Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer Double Mastectomies Do Not Lower Risk Of Death For Breast Cancer... After A Long And Dangerous Battle, Africa Has Been Declared Free... New Task Force Focuses on Quality of Life for AYAs with...
